Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 9 | 2020 | 51 | 2.820 |
Why?
|
| Liver Neoplasms | 8 | 2019 | 164 | 2.150 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2019 | 130 | 1.710 |
Why?
|
| Tissue and Organ Procurement | 4 | 2020 | 10 | 1.450 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 309 | 1.360 |
Why?
|
| Hepatectomy | 5 | 2019 | 26 | 1.330 |
Why?
|
| Organ Preservation | 3 | 2025 | 4 | 1.120 |
Why?
|
| Hemorrhage | 3 | 2012 | 259 | 0.970 |
Why?
|
| Tissue Donors | 3 | 2019 | 23 | 0.940 |
Why?
|
| Liver | 3 | 2019 | 415 | 0.790 |
Why?
|
| Liver Diseases | 2 | 2012 | 51 | 0.770 |
Why?
|
| Waiting Lists | 3 | 2020 | 9 | 0.750 |
Why?
|
| End Stage Liver Disease | 2 | 2020 | 9 | 0.730 |
Why?
|
| Biliary Tract | 1 | 2019 | 1 | 0.670 |
Why?
|
| Cholangiography | 1 | 2019 | 7 | 0.660 |
Why?
|
| Organ Preservation Solutions | 1 | 2019 | 1 | 0.650 |
Why?
|
| Hepatic Artery | 3 | 2016 | 4 | 0.610 |
Why?
|
| Policy Making | 1 | 2017 | 12 | 0.570 |
Why?
|
| Retrospective Studies | 12 | 2019 | 2444 | 0.570 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 73 | 0.550 |
Why?
|
| Perfusion | 2 | 2025 | 43 | 0.470 |
Why?
|
| Organ Transplantation | 2 | 2025 | 13 | 0.470 |
Why?
|
| Patient Selection | 4 | 2020 | 143 | 0.430 |
Why?
|
| Aged | 15 | 2017 | 5169 | 0.430 |
Why?
|
| Hemobilia | 2 | 2012 | 2 | 0.420 |
Why?
|
| Middle Aged | 16 | 2019 | 6825 | 0.420 |
Why?
|
| Polyarteritis Nodosa | 1 | 2012 | 1 | 0.410 |
Why?
|
| Aneurysm, Ruptured | 1 | 2012 | 17 | 0.400 |
Why?
|
| Humans | 28 | 2025 | 26856 | 0.380 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 133 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 189 | 0.370 |
Why?
|
| Treatment Outcome | 7 | 2017 | 2267 | 0.360 |
Why?
|
| Male | 18 | 2019 | 12866 | 0.350 |
Why?
|
| Duodenum | 2 | 2007 | 15 | 0.340 |
Why?
|
| Adult | 9 | 2019 | 7389 | 0.320 |
Why?
|
| Female | 18 | 2019 | 14462 | 0.320 |
Why?
|
| Time Factors | 6 | 2017 | 1564 | 0.300 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 2016 | 20 | 0.290 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 981 | 0.290 |
Why?
|
| Donor Selection | 2 | 2017 | 2 | 0.280 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2007 | 6 | 0.280 |
Why?
|
| Graft Rejection | 4 | 2017 | 33 | 0.280 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 18 | 0.270 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 21 | 0.270 |
Why?
|
| Graft Survival | 3 | 2017 | 27 | 0.270 |
Why?
|
| Stomach | 1 | 2006 | 42 | 0.260 |
Why?
|
| Aneurysm | 1 | 2006 | 25 | 0.260 |
Why?
|
| Pancreatectomy | 1 | 2006 | 55 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 108 | 0.240 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2020 | 46 | 0.240 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 213 | 0.240 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 457 | 0.220 |
Why?
|
| Aneurysm, False | 2 | 2016 | 18 | 0.210 |
Why?
|
| Young Adult | 4 | 2019 | 2584 | 0.190 |
Why?
|
| Risk Factors | 5 | 2017 | 2017 | 0.190 |
Why?
|
| Drainage | 2 | 2019 | 42 | 0.190 |
Why?
|
| Survival Rate | 3 | 2017 | 407 | 0.180 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2020 | 4 | 0.180 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 7 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 656 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 447 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 18 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 505 | 0.180 |
Why?
|
| Endoscopy | 1 | 2020 | 53 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 67 | 0.170 |
Why?
|
| Rupture, Spontaneous | 3 | 2008 | 10 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.160 |
Why?
|
| Embolization, Therapeutic | 2 | 2012 | 45 | 0.160 |
Why?
|
| Allopurinol | 1 | 2019 | 1 | 0.160 |
Why?
|
| Raffinose | 1 | 2019 | 1 | 0.160 |
Why?
|
| United Kingdom | 2 | 2017 | 70 | 0.160 |
Why?
|
| Adenosine | 1 | 2019 | 33 | 0.160 |
Why?
|
| Glutathione | 1 | 2019 | 68 | 0.160 |
Why?
|
| Population Surveillance | 1 | 2019 | 85 | 0.160 |
Why?
|
| Pandemics | 1 | 2020 | 166 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 115 | 0.160 |
Why?
|
| Bile Duct Diseases | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cold Ischemia | 1 | 2017 | 1 | 0.140 |
Why?
|
| Allografts | 1 | 2017 | 11 | 0.140 |
Why?
|
| Insulin | 1 | 2019 | 309 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Health Policy | 1 | 2017 | 59 | 0.130 |
Why?
|
| Age Factors | 2 | 2017 | 716 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2017 | 67 | 0.130 |
Why?
|
| United States | 2 | 2025 | 2035 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2017 | 252 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 472 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 2005 | 66 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2017 | 860 | 0.120 |
Why?
|
| Reoperation | 2 | 2013 | 144 | 0.120 |
Why?
|
| Adolescent | 2 | 2019 | 2960 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1090 | 0.110 |
Why?
|
| Victoria | 1 | 2013 | 2 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 225 | 0.100 |
Why?
|
| Adenoma, Liver Cell | 1 | 2012 | 1 | 0.100 |
Why?
|
| HELLP Syndrome | 1 | 2012 | 5 | 0.100 |
Why?
|
| Amylases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Digestive System Diseases | 1 | 2012 | 3 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2012 | 14 | 0.100 |
Why?
|
| England | 1 | 2012 | 34 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 1927 | 0.100 |
Why?
|
| Pancreatic Fistula | 1 | 2012 | 14 | 0.100 |
Why?
|
| Hemostatic Techniques | 1 | 2012 | 14 | 0.100 |
Why?
|
| Cysts | 1 | 2012 | 21 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2012 | 34 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2012 | 42 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2012 | 586 | 0.100 |
Why?
|
| Radiography | 1 | 2012 | 200 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2012 | 148 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 277 | 0.090 |
Why?
|
| Child | 1 | 2017 | 2152 | 0.090 |
Why?
|
| Cholecystolithiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 43 | 0.080 |
Why?
|
| Surgery Department, Hospital | 1 | 2009 | 12 | 0.080 |
Why?
|
| Pregnancy | 1 | 2012 | 1130 | 0.070 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2007 | 4 | 0.070 |
Why?
|
| Propionates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Chylous Ascites | 1 | 2007 | 3 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
|
| Pancreas | 1 | 2007 | 58 | 0.070 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2007 | 25 | 0.070 |
Why?
|
| Hepatoblastoma | 1 | 2006 | 6 | 0.070 |
Why?
|
| General Surgery | 1 | 2007 | 53 | 0.070 |
Why?
|
| Arteries | 1 | 2006 | 65 | 0.060 |
Why?
|
| Saphenous Vein | 1 | 2005 | 24 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2005 | 25 | 0.060 |
Why?
|
| Nursing Assessment | 1 | 2005 | 27 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2006 | 228 | 0.060 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 40 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2025 | 32 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2005 | 73 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 73 | 0.060 |
Why?
|
| Leg | 1 | 2005 | 131 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2005 | 104 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 465 | 0.050 |
Why?
|
| Stroke | 1 | 2005 | 233 | 0.050 |
Why?
|
| Splenorenal Shunt, Surgical | 1 | 2020 | 1 | 0.050 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 5 | 0.050 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2020 | 3 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cause of Death | 1 | 2020 | 66 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 38 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2020 | 45 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 18 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 19 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 358 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2017 | 605 | 0.040 |
Why?
|
| Death | 1 | 2017 | 8 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2012 | 1219 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2016 | 5 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 35 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 917 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 758 | 0.030 |
Why?
|
| Body Fluids | 1 | 2012 | 18 | 0.020 |
Why?
|
| State Medicine | 1 | 2009 | 3 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 20 | 0.020 |
Why?
|
| Workload | 1 | 2009 | 38 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 140 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 545 | 0.020 |
Why?
|
| Peritoneum | 1 | 2007 | 7 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 88 | 0.020 |
Why?
|
| Hepatic Veins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 16 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 94 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 156 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2007 | 116 | 0.020 |
Why?
|
| Acute-Phase Reaction | 1 | 2005 | 4 | 0.020 |
Why?
|
| Nursing Records | 1 | 2005 | 1 | 0.020 |
Why?
|
| Nursing Evaluation Research | 1 | 2005 | 7 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 11 | 0.020 |
Why?
|
| Skin Care | 1 | 2005 | 2 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 6 | 0.020 |
Why?
|
| Suppuration | 1 | 2005 | 5 | 0.020 |
Why?
|
| Observer Variation | 1 | 2005 | 43 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2005 | 111 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 113 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 848 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 963 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 367 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 342 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 496 | 0.010 |
Why?
|